Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Cash from Operations (2016 - 2025)

Celldex Therapeutics has reported Cash from Operations over the past 16 years, most recently at 63940000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 63940000.0 for Q4 2025, down 96.88% from a year ago — trailing twelve months through Dec 2025 was 210945000.0 (down 33.7% YoY), and the annual figure for FY2025 was 210945000.0, down 33.7%.
  • Cash from Operations for Q4 2025 was 63940000.0 at Celldex Therapeutics, down from 48628000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for CLDX hit a ceiling of 11930000.0 in Q2 2021 and a floor of 63940000.0 in Q4 2025.
  • Median Cash from Operations over the past 5 years was 28948000.0 (2023), compared with a mean of 32032750.0.
  • Biggest five-year swings in Cash from Operations: surged 46.03% in 2023 and later tumbled 191.35% in 2024.
  • Celldex Therapeutics' Cash from Operations stood at 14523000.0 in 2021, then crashed by 49.85% to 21762000.0 in 2022, then crashed by 49.49% to 32533000.0 in 2023, then grew by 0.18% to 32476000.0 in 2024, then plummeted by 96.88% to 63940000.0 in 2025.
  • The last three reported values for Cash from Operations were 63940000.0 (Q4 2025), 48628000.0 (Q3 2025), and 44005000.0 (Q2 2025) per Business Quant data.